New Pain Relief Gel Shows Promising Results in Clinical Trials
A Swedish pharmaceutical company, AlzeCure Pharma, has shared exciting new results from a clinical trial of its pain-relief gel, ACD440, […]
News
FDA Approves Updated COVID-19 Vaccines for High-Risk Groups
The FDA has approved updated COVID-19 vaccines from Pfizer, Moderna, and Novavax, but only for people at higher risk of
New Cancer Drugs in Development: Treeline Biosciences Raises $200 Million for Clinical Trials
Two experienced drug developers, Josh Bilenker and Jeff Engelman, have been working in secret for years on a new biotech
WHO Reports Highlight Global Mental Health Crisis and Need for Better Treatment
A new report from the World Health Organization (WHO) reveals that over one billion people worldwide suffer from mental health
New Hope for Liver Disease Patients: Groundbreaking Treatment Trial Begins
A new treatment for severe liver disease is being tested in humans for the first time. Resolution Therapeutics has started
New RNA Therapy Shows Promise for Rare Liver and Lung Disease
A new experimental RNA therapy from Wave Life Sciences has shown potential in helping patients with a rare genetic disorder
News
Astellas, a pharmaceutical company, disagrees with European authorities about their drug Izervay, which is meant to treat geographic atrophy, a type of eye disease.
Astellas and Apellis are two companies competing in the U.S. to treat geographic atrophy (GA), a serious eye condition that
News
After an earlier unsuccessful trial, EyePoint’s drug Duravyu shows promising results in treating diabetic macular edema (DME).
Earlier this year, EyePoint Pharmaceuticals faced setbacks when their drug-device combination, Duravyu, did not perform well in a study for
News
How Helping Patients Can Make the Switch to the New Part D in 2025 Easier
Here’s a simplified version of the text: **Key People at IQVIA** – Nancy McGee: VP of U.S. Patient Support Services
News
Regulatory Update: NICE Approves New Medications from Pfizer and AstraZeneca
Welcome to Fierce Pharma’s 2024 regulatory tracker. We’re keeping track of the approval progress for pharmaceutical products, including their expansion